Affordable Access

deepdyve-link
Publisher Website

Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial.

Authors
  • Sriprayoon, Tassanee1, 2
  • Mahidol, Chulabhorn1, 3
  • Ungtrakul, Teerapat1
  • Chun-On, Pattra1
  • Soonklang, Kamonwan1
  • Pongpun, Wanvisa1
  • Laohapand, Charlie1, 2
  • Dechma, Jiraporn1
  • Pothijaroen, Charinthip1
  • Auewarakul, Chirayu1, 2
  • Tanwandee, Tawesak2
  • 1 Chulabhorn Hospital, Bangkok, Thailand.
  • 2 Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • 3 Chulabhorn Research Institute, Bangkok, Thailand.
Type
Published Article
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
Publication Date
March 2017
Volume
47
Issue
3
Identifiers
DOI: 10.1111/hepr.12743
PMID: 27176630
Source
Medline
Keywords
License
Unknown

Abstract

Both ETV and TDF showed potent antiviral activity against hepatitis B. Either ETV or TDF can be recommended as a treatment of choice for patients with chronic hepatitis B. Both drugs were safe and well tolerated.

Report this publication

Statistics

Seen <100 times